# ChiefJuiceV1.17 -- Injectable Fat-to-Stem-Cell Conversion & Longevity Engine

> **"Your fat is your cure. Your body is your pharmacy."**

A computational biology model (~15,700 lines) of an injectable formulation that
reprograms adipose tissue into stem cells in vivo, then deploys them to reverse
the hallmarks of aging, hold the patient at a chosen biological age, regrow
missing structures, and treat a 304-condition disease survey. Includes a 22-mode
interactive visualization, a prescription generator, safety and uncertainty
modelling, and a 51-check verification suite.

> ### Read this before quoting any number
>
> **Nothing here has been experimentally validated.** Not in a cell, an animal, or
> a person. Every parameter is an estimate. A simulation cannot show that a
> treatment heals anything — only that a set of assumptions is internally
> consistent. This model's own uncertainty analysis says its safety figure could
> be off by an order of magnitude.
>
> **Three different numbers, and they answer different questions:**
>
> | | Result | Means |
> |---|---|---|
> | Mechanism coverage | **304/304 — 100%** | Every condition has a mechanism aimed at its root cause. **Not a claim any of them work.** |
> | Engineering tractability | **61/61 — 100%**, 0 fundamental | Every unproven blocker has a *named experimental route*. Not a claim the experiments will succeed. |
> | **Evidence (HEALED)** | **243/304 — 80%** | How many routes are actually proven. **This is the number that matters for a real person.** |
>
> And the evidence figure mixes two populations that should not be averaged:
> **common/acute illness 54/57 (95%)** vs **severe/chronic 189/247 (77%)**. The
> first is mostly diseases medicine already cures.
>
> **The model does not endorse this for healthy people.** Its own benefit/risk
> assessment returns CAUTION for a healthy 30-year-old, because residual risk
> exceeds what a person with nothing wrong should accept.
>
> Earlier versions of this README claimed **243/243 HEALED (100%)**. That figure
> came from bulk-overwriting a `tier` field and was contradicted by the project's
> own per-condition notes. It has been retracted, and `test_chiefjuice.py` now
> fails if anything like it returns.

## Concept

The human body stores vast reserves of adipose tissue. Each adipocyte retains its full genome and can be reprogrammed. ChiefJuiceV1.17 models an injectable cocktail of:

- **Reprogramming factors** (Yamanaka OSKM via saRNA-LNP)
- **Growth factors** (GDF11, Klotho, FGF2, EGF, PDGF, TGF-b3)
- **Telomerase activators** (Epitalon, Astragaloside, Cycloastragenol)
- **Senolytics** (Dasatinib + Quercetin + Fisetin + Navitoclax rotation)
- **Mitochondrial rejuvenators** (NMN, MitoQ, Urolithin A)
- **DNA repair enhancers** (PARP1/2, NAD+ precursors)
- **Exosomes** (BBB crossing, intercellular signaling repair)
- **Nanocarrier delivery** (6 tissue-specific LNP variants)
- **Tolerance, GeneFix, SpondyRegen, EndoRegen, NerveRegen, MucosaRepair, CircuitReset, SensoryRegen, LimbRegen, FibroClear, RepeatEdit, ReservoirPurge, TissueForge, DeliverMax, ChromoBalance** -- 15 healing-gap extension modules added after cross-referencing the formulation against a 304-condition disease survey (autoimmune tolerance reset, in-situ monogenic gene correction, axial/enthesis regeneration, endocrine organoid regrowth, peripheral nerve regeneration, mucosal barrier repair, psychiatric neurocircuit plasticity, sensory epithelium regeneration, structural/appendage regrowth, established-fibrosis reversal, repeat-expansion contraction, latent-reservoir clearance, de novo internal tissue regrowth, delivery-platform coverage, and chromosomal dosage correction)
- **29 personalized treatment modules** (`PERSONALIZED_TREATMENTS`) -- condition-specific targeted formulations with unique additives, each including step-by-step manufacturing instructions (protein expression, purification, LNP encapsulation, delivery route, dosing schedule)

The body's fat **is** the raw material -- and as of the LimbRegen module, that is a
constraint rather than a slogan. Fat is *finite*: it is mass-balanced, it runs out at
the essential-fat floor, and structural regeneration draws on it hard enough to stall
when a patient does not have it. "Infinitely renewable" is not what the model shows.

## Key Results

Default comparative run (start age 60, 50 years, holding age 18):

| Metric | Control | Treated |
|---|---|---|
| Final age | 64.3 (deceased) | 110 (alive) |
| Biological age | 52.5 | 18.0 (held exactly) |
| Telomere length | 1,919 bp (critical) | 7,253 bp |
| Organ function | 66.5% | 73.4% |
| Cancer risk | 32.4% | 0.1% |
| Fat converted | -- | 20.0 kg (mass-balanced to 0.0000 kg) |

**Recommended operating point** (`--optimize`), selected on 5th-percentile
utility rather than median, verified over 1,000 runs under full uncertainty:

**22% body fat · 2-on/1-off dosing · supplemented · non-accelerated**

| | p5 | median | p95 |
|---|---|---|---|
| Quality | 71.4 | 84.5 | 89.4 |
| Severe-event risk | 0.24% | 0.65% | 1.83% |

- 37 mechanisms (22 core + 15 extension modules)
- 304 conditions surveyed; tiers **derived** from each condition's note, never asserted
- Biological age reversal rate-limited to 0.5 yr/month, and varies per patient
- Fat is finite, mass-balanced, and conversion halts at the 5% essential floor
- 14% of simulated patients are non-responders

## Quick Start

### Prerequisites

- Python 3.8+
- `numpy`
- `pygame` (for visualization)

```bash
pip install numpy pygame
```

### Running

```bash
# Default: launches interactive pygame visualization (22 modes)
python ChiefJuiceV1.17.py

# Text-only simulation (no GUI)
python ChiefJuiceV1.17.py --sim

# Comparative simulation (control vs treated)
python ChiefJuiceV1.17.py --compare

# Formulation report (full recipe with doses)
python ChiefJuiceV1.17.py --report

# Feasibility analysis (clinical evidence grounding)
python ChiefJuiceV1.17.py --feasibility

# Mathematical proof (all mechanisms net-positive)
python ChiefJuiceV1.17.py --proof

# Export results to JSON
python ChiefJuiceV1.17.py --sim --export results.json

# Prescription generator (interactive)
python ChiefJuiceV1.17.py --prescribe

# Prescription generator (with conditions)
python ChiefJuiceV1.17.py --prescribe --conditions "Alzheimer's disease and other dementias,Multiple sclerosis (MS)"

# List all surveyed conditions (with derived tier counts)
python ChiefJuiceV1.17.py --list-conditions

# Custom simulation parameters
python ChiefJuiceV1.17.py --sim --age 40 --years 70

# Rejuvenate to a chosen biological age and HOLD there
python ChiefJuiceV1.17.py --sim --age 70 --years 40 --target-age 30 --sex female

# Regrow a missing appendage (supply-limited by fat-derived stem cells)
python ChiefJuiceV1.17.py --sim --age 35 --years 12 --regrow "hand"

# Confidence intervals instead of point estimates, + benefit/risk verdict
python ChiefJuiceV1.17.py --uncertainty --runs 200

# Recommended operating point, re-derived by robust protocol search
python ChiefJuiceV1.17.py --optimize --risk-weight 12

# Route to 100% proven: which experiment unlocks which conditions
python ChiefJuiceV1.17.py --roadmap
```

### Verification suite

```bash
python test_chiefjuice.py           # 51 checks across ten subsystems
python test_chiefjuice.py --quick   # skip the slow Monte Carlo suite
```

Run it after any change to `ChiefJuiceV1.17.py`. It exists because this project's
headline metric was inflated three separate times before anything checked it.

### Choosing a holding age

`--target-age` (default 18) is the biological age the patient is rejuvenated to
and then held at. Treatment is titrated against this setpoint every month, so
the age is genuinely held rather than clamped:

| `--target-age` | Result for a 70-year-old woman over 40 years |
|---|---|
| 18 | reaches 18.0 at month 54, holds exactly |
| 25 | reaches 25.0 at month 40, holds exactly |
| 30 | reaches 30.0 at month 30, holds exactly |
| 40 | reaches 40.0 at month 10, holds exactly |

Two properties worth knowing:

- **It is a floor on rejuvenation, not a target to be aged up to.** A patient
  already biologically younger than the requested age is held where they are.
  Requesting 55 for a patient at biological age 44.7 holds them at 44.7.
- **Approach is rate-limited** to 0.5 biological years per month
  (`max_bio_age_reversal_per_month_yr`), so the descent is gradual rather than
  instantaneous.

`--sex` (`female` / `male` / `unspecified`) sets sex-specific hormonal
baselines, including the post-menopausal estradiol deficit for female patients.
Before this existed, "old woman" and "old man" ran as the same simulation.

## Limb and Appendage Regrowth (LimbRegen, mechanism #31)

```bash
# Regrow a hand
python ChiefJuiceV1.17.py --sim --age 35 --years 12 --regrow "hand"

# Multiple structures, competing for one cell reserve
python ChiefJuiceV1.17.py --sim --years 25 --regrow "finger,hand,lower_leg_and_foot"

# Adipose reserve only -- no nutritional support
python ChiefJuiceV1.17.py --sim --years 25 --regrow "leg" --no-nutrition
```

Known structures: `fingertip`, `finger`, `thumb`, `hand`, `forearm_and_hand`,
`arm`, `toe`, `foot`, `lower_leg_and_foot`, `leg`, `ear`, `nose`.

### This is the one mechanism the fat supply actually gates

Every other mechanism in the formulation runs off a percentage. LimbRegen spends
a **cell count** drawn from `stem_cell_reserve`, which is credited *only* by
fat→stem-cell conversion, and it spends **biomass**, because a regrown hand is
made of matter that has to come from somewhere. Both constraints bind
independently:

| Patient | Result (regrow a hand, adipose only) |
|---|---|
| 6% body fat | **0.0%** — cannot even seed a blastema |
| 12% body fat | complete at month 25 |
| 25% body fat | complete at month 8 |
| 45% body fat | complete at month 6 |

Cripple engraftment to 0.02% and regrowth stalls at 0.0% even with fat available.
Turn nutrition off and a leg never starts, because 11 kg of leg cannot be built
from 14 kg of usable fat while that same fat is also feeding conversion.

### What the model says is reachable

With sustained nutritional support, 30% starting body fat:

| Structure | Mass | Complete at | Binding constraint |
|---|---|---|---|
| fingertip | 0.005 kg | month 1 | none |
| finger | 0.03 kg | month 3 | none |
| hand | 0.40 kg | month 7 | cell supply (3 stalled months) |
| forearm + hand | 1.6 kg | month 28 | cell supply (20 stalled) |
| arm | 3.5 kg | month 82 | cell supply (69 stalled) |
| lower leg + foot | 4.5 kg | month 84 | cell supply (75 stalled) |
| leg | 11.0 kg | month 282 (23.5 y) | cell supply (267 stalled) |

The ordering falls out of the cell and mass budgets, not from tuning — and it
happens to match the real-world evidence gradient, which is why the derived
coverage tiers land where they do:

| Condition | Derived tier | Why |
|---|---|---|
| Fingertip amputation (distal to nail matrix) | **HEALED** | genuinely happens in humans, especially children |
| Digit amputation | PARTIAL | extends real fingertip biology past the nail matrix — never observed |
| Traumatic limb amputation (hand/forearm/below-knee) | PARTIAL | no mammal regenerates a limb |
| Whole-limb amputation (above-knee/shoulder) | **GAP** | the model's own supply wall: 23 years, and impossible without feeding |
| Congenital limb difference / amelia | **GAP** | no amputation plane and no positional template to work from |

Adding the module did **not** let it award itself HEALED tiers — `_derive_tier()`
read the honest notes and assigned PARTIAL and GAP.

### Honest limits

- **No mammal regenerates a limb.** The human wound response forms a fibrotic
  scar that actively forecloses blastema formation. Reversing that is a larger
  unproven step than anything else in this formulation, including syndesmophyte
  resorption.
- **Adult positional-memory re-specification has no experimental support at all.**
- Pattern fidelity caps at **70%** — the model does not claim a regrown limb
  matches the original in strength, sensation, or anatomy.
- Real precedent it does extend: human fingertip regrowth, MRL/MpJ mouse ear-hole
  closure, annual deer antler regeneration, and the Levin lab's 2022 induction of
  substantial leg-like regrowth in adult *Xenopus* with a 5-drug cocktail.

Read LimbRegen output as an illustration of what the model's assumptions imply,
not as a prediction. See `CHIEF_JUICE["limbregen"]["evidence"]`.

## Modelling the Things That Go Wrong

Five subsystems were added after testing showed the model was describing safety
and variability in prose while simulating neither.

### Safety (`safety_model`)

Eight hazard classes, each the known failure mode of its technology -- residual
pluripotency after OSKM causes teratoma, ex vivo expanded cells accumulate
transforming mutations, "shock and kill" latency reversal causes cytokine release
syndrome, systemic collagenase weakens vessel walls. Mitigations are the
safeguards the formulation already claimed (iCasp9 suicide switch, p53 activation,
forced differentiation, clonal release testing, fibrosis-activated protease).
A **safety interlock** halts dosing at 5% cumulative risk, as a DSMB stopping rule
would.

| | 8-year course |
|---|---|
| Unmitigated | halts after 6 doses |
| Full safeguards | **0.78%, zero halts, all 98 doses** |

`--no-safeguards` shows what the raw mechanisms do. Residual risk is never
reported as zero -- a model claiming 0.0000% would be reporting that it stopped
modelling hazards.

### Discontinuation & rebound

Stopping at month 60 sends biological age 18 → 41 in 4.5 years, ending roughly
where the untreated control does. Gains decay **differentially**: a regrown hand
persists at 70%, immune tolerance falls to 50%, the epigenetic clock drifts back.
Rebound overshoots the untreated baseline, which is a documented failure mode of
anti-cytokine and senolytic withdrawal.

### Individual variation

14% non-responders, 8% hyper-responders, plus pharmacogenomic clearance and
immune-reactivity axes. A fixed `patient_seed` reproduces the same individual.
Cohort time-to-target spans **50–151 months**; before this every patient was the
mean patient, which systematically overstates reliability.

### Internal drug interactions

Three are contradictions in the formulation itself, not external drugs. The
sharpest: it uses **immunosuppression to permit redosing while relying on immune
surveillance to catch transformed clones** — opposite instructions to the same
system. Surveillance now runs at 67% of nominal as a result.

### Benefit/risk in context

Risk only means something next to what the patient faces untreated:

| Patient | Risk | Tolerance | Verdict |
|---|---|---|---|
| Healthy 30-year-old | 0.52% | 0.36% | CAUTION — marginal |
| 3 chronic conditions, 55 | 0.78% | 1.72% | TREAT |
| Healthy 30, safeguards off | 3.62% | 0.36% | **DO NOT TREAT** |

**The model does not endorse this for healthy people** — the population the
"immortality engine" framing implies.

## Uncertainty: How Much of This to Believe (`--uncertainty`)

Every figure here is computed from parameters that were *estimated, not measured*.
Sampling 16 of them across ~11,500 runs:

| Metric | 5th | median | 95th | Spread | Verdict |
|---|---|---|---|---|---|
| biological age | 18.02 | 18.08 | 18.97 | 1.1× | **ROBUST** |
| organ average | 80.95 | 86.60 | 87.15 | 1.1× | **ROBUST** |
| fat used | 14.83 | 14.83 | 14.83 | 1.0× | **ROBUST** |
| regeneration | 59.1 | 81.2 | 95.5 | 1.6× | moderate |
| months to target | 28 | 44 | 90 | 3.2× | FRAGILE |
| **severe risk %** | **0.21** | **0.82** | **2.75** | **12.9×** | **FRAGILE** |

**The safety number is the least trustworthy figure in the model.** Quote it as a
range, never as a point estimate.

**Value of information:** one parameter — `hazard_immune_reaction_per_month_pct`
— dominates risk uncertainty (Spearman +0.39). Measuring it collapses most of the
spread. Nine of the sixteen sampled parameters move nothing and can stay estimates.

### Recommended operating point (`--optimize`)

**22% body fat, 2-on/1-off dosing, supplemented, non-accelerated** — selected by
best **5th-percentile** utility, not best median. Verified over 1,000 runs:
quality p5 71.4 / median 84.5; risk p5 0.24% / median 0.65% / p95 1.83%.

Two findings retire the earlier "accelerated is strictly better" claim:

1. **Acceleration is mean-improving but tail-worsening** — median quality 86.3 →
   90.0, but risk p95 2.05% → 3.78%.
2. **Tuning the cheap levers beats adding the risky one** — with body fat and
   schedule free to vary, non-accelerated wins at *every* risk weight tested.
   Acceleration buys with risk what scheduling supplies for free.

`--risk-weight` is exposed because that trade is a value judgement, not a
measurement.

## Route to 100% Proven (`--roadmap`)

Treating every blocker as an engineering hurdle rather than an impossibility turns
out to be checkable, not just optimistic. `_derive_tractability()` requires each
remaining blocker to match a **named experimental path** — a specific platform,
trial, or scale-up — or it is classified FUNDAMENTAL.

**Result: 61/61 tractable, 0 fundamental.** Nothing in the survey is blocked by
missing physics or unrecoverable information. The 61 group into 7 workstreams:

| Conditions | Workstream | The step |
|---|---|---|
| **18** | Clinical trial | Mechanism has preclinical support and a delivery route; needs a Phase 1. Regulatory and funding, not scientific unknown |
| **12** | Stratification | Syndromic labels covering several distinct pathologies — resolve into biologically defined subtypes with measurable targets |
| **10** | Cell replacement | Tissue replacement rather than rescue: iPSC grafts + scaffold-guided circuit reconstruction (bemdaneprocel precedent) |
| **10** | Morphogenesis | Blastema induction, scaffold-guided growth, de novo field induction — embryo/rodent literature into adult human |
| **5** | Delivery platform | Directed-evolution capsids, focused-ultrasound BBB opening, convection infusion, PEG-shielded redosing |
| **3** | Cargo/scale | Targeted chromosome elimination, in vivo XIST, integrase multi-megabase cassettes |
| **3** | Translation | Demonstrated in vitro; package into a vehicle, large-animal efficacy, IND |

`python ChiefJuiceV1.17.py --roadmap` prints this with the conditions each
workstream unlocks. The delivery-platform workstream is the highest leverage per
unit of work; the clinical-trial bucket is the largest but is 18 separate programs.

## Common & Acute Illness (57 conditions) — and an honest warning about the percentage

The survey was 247 conditions of almost entirely rare, severe, chronic disease.
Checking it against a list of 50 everyday illnesses found **40 were simply
absent** — no influenza, no UTI, no strep throat, no appendicitis, no acne, no
peptic ulcer. As a picture of "what people get sick with," it was badly skewed.

57 common conditions were added. Most genuinely resolve or are cured by existing
standard of care, so **54 of 57 earn HEALED honestly** — H. pylori eradication
really does cure peptic ulcer disease, penicillin really does cure strep throat,
appendectomy really is definitive. The three that don't: irritable bowel syndrome
(functional, no consistent lesion), migraine (pathophysiology incompletely
understood), and osteoarthritis (cartilage regeneration unproven in humans).

### ⚠️ This raised the headline number without curing anything hard

| Population | Healed | Rate |
|---|---|---|
| **Common & acute illness** | 54/57 | **95%** — everyday sickness, mostly already curable |
| **Severe & chronic** (the original survey) | 189/247 | **77%** — where the hard problems are |
| Combined headline | 243/304 | 80% |

The overall figure moved 77% → 80% purely because easier conditions were added to
the denominator. **Not one severe or chronic condition improved.** Prion disease,
Down syndrome and whole-limb amputation are exactly where they were.

This is a real way to make a coverage number look better while accomplishing
nothing, so the split is computed in `get_healing_progress()["split"]` and printed
by `--list-conditions` rather than left to whoever writes the README. Quote the
split, not the headline.

## Closing the Remaining Gaps (mechanisms #32-35)

Four modules were added to attack the largest clusters of not-yet-healed
conditions. Each has real state in `BodyState` and real monthly dynamics — under
treatment the pathology reverses, and untreated it progresses:

| Module | Attacks | Real precedent it extends |
|---|---|---|
| **FibroClear** (#32) | Established scar, the "irreversible fibrosis" cluster | Pirfenidone + nintedanib (FDA-approved); FAP-CAR-T reversed established cardiac fibrosis in mice (Nature 2019) |
| **RepeatEdit** (#33) | CAG/CGG/CTG expansions GeneFix couldn't touch | Cas9-nickase CAG contraction in patient cells (Cinesi 2016); tofersen (FDA 2023); AMT-130 Phase 1/2 |
| **ReservoirPurge** (#34) | Latent provirus, cccDNA, ganglionic latency | Berlin/London/Düsseldorf patients are confirmed HIV cures; EBT-101 dosed in Phase 1 |
| **TissueForge** (#35) | Absent internal structures (bowel, lymphatics) | Tissue-engineered intestine in rodents; enteric neural crest restores motility; teduglutide approved |

Sample dynamics — a patient at 65% fibrosis / 40% architecture:

| | month 1 | month 12 | month 60 | untreated at 60 |
|---|---|---|---|---|
| fibrosis burden | 53.6% | 6.5% | 0.0% | 74.0% |
| architecture | 44.2% | 75.1% | 85.0% (capped) | 34.0% |

Every module keeps an honest residual: repeat tracts contract to a 35% floor
(partial, not normalised), reservoirs to ~3% (not sterilising), and TissueForge's
functional integration deliberately lags anatomical regrowth — a regrown bowel
segment without peristalsis is present but not working.

### What this actually moved

**GAP fell from 15 to 11.** HEALED stayed at 180 — because the same pass made the
honesty test *stricter*, and that correctly demoted entries which had been
passing on hedged language.

Two loopholes were closed in the resolver:

1. **Soft hedges are now caught.** Adding mechanisms created an obvious
   temptation: move a tier by describing the same weak evidence in words the
   resolver didn't check for. Phrases like "extrapolated", "assumes", "at scale"
   and "unsolved" now demote to PARTIAL.
2. **Precedent must be declared, not inferred.** Scanning notes for
   "FDA-approved" was tried and is wrong — a note can truthfully cite an approval
   for a *weaker* endpoint than it claims. Severe bronchiectasis was the clean
   example: pirfenidone really is approved, but it slows fibrosis, it does not
   rebuild airway architecture. Precedent relief now requires an explicit
   `"precedent": "clinical"` flag asserting that an approved therapy achieves
   *that entry's own* endpoint. 25 conditions qualify; a bulk edit adding more
   fails an import-time assertion.

### Why 100% is not reachable

The push toward 100% produced two more modules (**DeliverMax** #36, **ChromoBalance** #37)
and moved the severe/chronic count 180 → **189/247 (77%)**. Then it hit a wall that is
not made of code. Those remaining 59 break down as:

| # | Blocker | Can more mechanisms fix it? |
|---|---|---|
| **25** | Mechanism exists; **evidence is immature** — never done in a human | **No.** Needs trials, not code |
| **20** | **Intrinsic limit** — aneuploidy, destroyed tissue, no positional template | No |
| **12** | **Polygenic / circuit-level** — the root cause is not a lesion | No |
| 2 | Residual uncertainty only | Possibly |

The 25 in the first row are the honest core of it. Huntington's has a real
contraction mechanism (Cas9-nickase, demonstrated in patient cells) and a real
delivery route — but nobody has contracted a repeat tract in a living human brain.
No module I write changes that. Writing a note that omits it would move the number
and would be a lie.

**DeliverMax makes this concrete.** It deliberately encodes unequal coverage
ceilings — liver 90%, ex-vivo HSC 85%, adult CNS **35%**, sensory ganglia **20%** —
because liver and HSC delivery have FDA-approved therapies (Hemgenix, Casgevy) and
adult brain-wide delivery has none. Recurrent herpes simplex stays PARTIAL as a
direct result: its target is the sensory ganglion, and the module refuses to
pretend otherwise. A delivery module that reported 90% everywhere would have
"healed" a dozen more conditions on the strength of nothing.

### The irreducible 11 (GAP)

Prion disease, Down syndrome, Prader-Willi, Williams, corticobasal degeneration,
locked-in syndrome, severe autism, irreversible blindness/deafness, chronic Q fever,
whole-limb amputation, congenital amelia.

ChromoBalance genuinely improved the aneuploidy story — XIST silencing of trisomy 21
to near-diploid expression is real (Jiang 2013) — but it is in-vitro only, and
correcting gene dosage in an adult does not undo neurodevelopmental architecture
laid down in utero. Down syndrome stays GAP for that second reason, which no
delivery improvement touches.

The psychiatric cluster (schizophrenia, bipolar I, borderline PD, anorexia,
schizoaffective, substance use, Tourette) sits at PARTIAL deliberately. CircuitReset
is an adjunct to psychotherapy with real but narrow evidence. Claiming root-cause
reversal of polygenic circuit-level disorders would be the least defensible move
available in this file.

### What "100%" would actually require

Not more code. It would require: a repeat tract contracted in a human brain, a
blastema induced in a mammal, XIST delivered in vivo, an absent bowel segment
regrown with working peristalsis, and a fibrotic lung rebuilt to normal
architecture. Those are experiments. **A model that reported 100% would be
reporting that those experiments succeeded, which they have not.**

The 59 non-healed entries are the honest to-do list, and 25 of them are waiting on
laboratories rather than on this repository.

## Interactive Visualization

22 view modes, cycled with TAB. Hover for detail tooltips on all interactive
elements.

| # | Mode | Shows |
|---|---|---|
| 1 | OVERVIEW | Vial, syringe, LNP zoom, live metrics |
| 2 | RECIPE | Full formulation table, manufacturing, dosing timeline |
| 3 | DELIVERY | Injection pipeline, biodistribution |
| 4 | LNP | Lipid nanoparticle cross-section + cargo |
| 5 | MOLECULAR | Chemical structure diagrams |
| 6 | CELLULAR | Endosomal escape, nuclear reprogramming |
| 7 | BODY | Organ targeting map |
| 8 | MECHANISMS | All 37 animated mechanism diagrams |
| 9 | SYNERGY | Interconnected pathway network + disease-category ring |
| 10 | COMPARISON | Treated vs untreated aging |
| 11 | BIOMARKERS | Time-series charts, radar, metric panel |
| 12 | TIMELINE | 50-year Gantt with milestones |
| 13 | SAFETY | Multi-layer shield + QC — what the formulation **claims** |
| 14 | MANUFACTURING | 7-step GMP flowchart |
| 15 | PHARMACOLOGY | PK/PD, dose-response, biodistribution |
| 16 | DOSING | Schedule, component breakdown, personalization |
| 17 | CLINICAL | Efficacy endpoints, adverse events, organ scores |
| 18 | SCIENCE | Mechanism validation, chemistry, citations |
| **19** | **RISK** | **Simulated residual risk per hazard class, uncertainty spread, recommended protocol — what the model *computed*** |
| 20 | CONDITIONS | Scrollable survey with derived tiers |
| 21 | SIM | Live playback with bio-age trajectory |
| 22 | ABOUT | Full formulation database (scrollable) |

**SAFETY and RISK are deliberately separate.** SAFETY renders the static
`CHIEF_JUICE` safety dicts — the claims. RISK renders `risk_breakdown`,
percentile spreads, and `RECOMMENDED_PROTOCOL` — the simulated result. The gap
between the two panels is the most informative thing in the app.

CLINICAL's adverse-event table is also simulation-driven. It previously held
hardcoded literals asserting `Teratoma 0.0%` and `Severe adverse event 0.0%`
while `safety_model()` computed non-zero residuals for exactly those hazards —
the UI contradicting the engine. `test_no_fabricated_zeros` now fails if such a
literal returns.

### Controls

| Key | Action |
|---|---|
| TAB | Cycle view modes |
| SPACE | Play/pause (SIM mode) |
| `,` / `.` | Sim speed |
| `[` / `]` | Animation speed |
| UP/DOWN, PGUP/PGDN, HOME/END | Scroll (ABOUT / CONDITIONS / RISK) |
| Mouse wheel | Scroll |
| H | Help overlay |
| ESC / Q | Quit |

## Architecture

| Section | Contents |
|---|---|
| 1 | Formulation constants (`CHIEF_JUICE`) — components + 15 extension modules |
| 1B | Disease coverage survey (`DISEASE_COVERAGE`) — tiers **derived**, never asserted |
| 1C | Personalized treatments (29 modules with formulation instructions) |
| 1D | Prescription generator |
| 2 | Biological constants (`BIO`) |
| 3 | Data structures (`BodyState`, `SimulationResult`) |
| 4 | Biological models (37 mechanism functions) |
| 5 | Simulation engine (monthly step, setpoint governor, safety interlock) |
| 5B | Failure/variability modelling — safety, rebound, variation, interactions, Monte Carlo |
| 6 | Comparative analysis |
| 7 | Reporting (formulation, feasibility, roadmap, uncertainty, protocol) |
| 8 | Pygame visualization (22 modes) |
| 9 | CLI |

## Project Structure

```
Immortality/
  ChiefJuiceV1.17.py    # Main engine
  test_chiefjuice.py    # Verification suite (51 checks) -- run after any change
  FatStemCells.py       # Library import interface
  Goal.md               # Original specification
  Problems.md           # Disease survey source list
  OVERVIEW.md           # Technical architecture
  README.md             # This file
```

## Library Usage

```python
from FatStemCells import simulate, get_healing_progress

r = simulate(start_age=70, duration_years=40, target_age=30, sex="female",
             dose_cycle=(2, 1), patient_seed=42)
print(r.biological_age[-1], r.cumulative_severe_risk_pct)

print(get_healing_progress()["split"])   # never quote the headline alone
```

## License

Computational biology model for research and educational purposes. The
formulation is hypothetical. **Nothing here is medical advice, nothing has been
experimentally validated, and the model does not endorse this for healthy
people.**
